Antibodies

09 Nov 2018 TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting
08 Nov 2018 Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data
08 Nov 2018 Immunomedics Expands Clinical Collaboration With Astrazeneca to Include Metastatic Non-Small Cell Lung Cancer
07 Nov 2018 Fortis Therapeutics Receives FDA Clearance of Two IND Applications for Novel Anti-CD46 Therapeutic for Treatment of Late-Stage Prostate Cancer and Multiple Myeloma
07 Nov 2018 ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors
07 Nov 2018 Aridis Pharmaceuticals Announces Publication of Positive AR-301 Phase 1/2a Data in "Intensive Care Medicine" and "The Lancet Respiratory Medicine"
07 Nov 2018 Oncobiologics Advances ONS-5010 into wet AMD Clinical Trial
07 Nov 2018 U.S. Food and Drug Administration Approves Empliciti® (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myeloma
07 Nov 2018 Momenta Pharmaceuticals Announces Global Settlement with AbbVie to Enable Commercialization of M923, a Proposed Biosimilar to HUMIRA® (adalimumab)
07 Nov 2018 Early Phase 1 Data from Merck’s Oncology Pipeline for Investigational Anti-LAG-3 Therapy (MK-4280) and Anti-TIGIT Therapy (MK-7684) to Be Presented at SITC’s 33rd Annual Meeting
05 Nov 2018 Seattle Genetics Submits Supplemental Biologics License Application for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
03 Nov 2018 Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs
02 Nov 2018 OSE Immunotherapeutics Regains Worldwide Rights to its CD28 antagonist FR104 from Janssen Biotech
01 Nov 2018 Bio-Thera Solutions Announces Initiation of Pivotal Phase III Study of BAT8001 for Patients with Metastatic Breast Cancer
01 Nov 2018 GT Biopharma Receives FDA Clearance to Commence First-in-Human Phase 1 Study of its First-in-Class Tri-Specific Killer Engager (TriKE), GTB-3550, for the Treatment of Acute Myelogenous Leukemia, Myelodysplatic Syndrome and Mastocytosis
01 Nov 2018 Forty Seven Inc. Announces Publication in The New England Journal of Medicine of 5F9 Phase 1b Clinical Data in Non-Hodgkin’s Lymphoma (NHL)
01 Nov 2018 Adagene Announces First Patient Dosed in United States and Acceptance of IND in China for ADG-106
31 Oct 2018 Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz)
31 Oct 2018 OSE Immunotherapeutics Presents Selective SIRP-alpha antibodies: OSE-172, a next-generation myeloid checkpoint inhibitor at the World Immunotherapy Congress
31 Oct 2018 Galderma Announces Positive Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis
31 Oct 2018 Alligator Bioscience Expands Pipeline: Preclinical Development Initiated for the Candidate Drug ATOR-1144
31 Oct 2018 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
30 Oct 2018 NeoImmuneTech Announces Initiation of Clinical Trial for HyLeukin-7 Treatment in Combination with Standard Therapy for Newly Diagnosed Brain Cancer Patients
30 Oct 2018 Genmab Announces Positive Topline Results in Phase III MAIA Study of Daratumumab in Front Line Multiple Myeloma
29 Oct 2018 OSE Immunotherapeutics Announces Publication in Nature Communications on Anti-IL-7 Receptor Antagonist (OSE-127)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top